An international study led by Memorial Sloan Kettering found that pazopanib (Votrient®) controls cancer as effectively as sunitinib (Sutent®) while improving patients’ quality of life.
Memorial Sloan Kettering urologic surgeon Pramod Sogani has been inaugurated as President of the American Urological Association. In this Q&A he discusses his goals and his new role.
A study has found that the majority of kidney cancer patients with small tumors have their entire kidney removed, which can increase the risk of developing chronic kidney disease and cardiovascular complications.
Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.